Cardiovascular effects: Glucagon receptor agonism (via retatrutide) and GLP-1 receptor agonism have been associated with modest increases in heart rate as a class effect
NuRev Peptides does not make claims regarding outcomes, efficacy, or safety related to this product
Discontinue if: Significant adverse reactions occur, you achieve body composition goals, no response after 8-12 weeks at optimal dosing, medical contraindications develop, or pregnancy occurs
Hematology focuses on blood-related conditions, including anemia, clotting disorders, and deficiencies that affect oxygen transport in the body
Clinical research suggested doses in the range of 1-10mcg per kilogram of body weight showed efficacy, though most protocols standardized around 4-6mcg/kg for practical application
In laboratory and pre-clinical settings, AOD9604 has been studied across several distinct biological systems